09.07.23 -- New FDA Postmarketing Data On Underrepresented Populations Guidelines

Explore the primary factors institutions should consider to navigate impending CMS changes and what to anticipate for the future of enrollment for Medicaid beneficiaries.

Get a global overview of the cell and gene therapy regulatory landscape, including pipeline, late-stage, and approved products, covering cells, genetically modified cells, and gene therapies.

Delve into the key considerations for delivering an integrated preclinical and clinical abuse potential drug development evaluation that meets EMA and FDA regulatory requirements.

As one of the world’s largest and most experienced safety and PV organizations, discover how IQVIA is bringing extensive domain expertise and deep regulatory intelligence to the life sciences industry.

Veristat’s regulatory publishing team offers extensive expertise across the full scope of regulatory requirements, including your applications, amendments, supplements, and reports.

How do you handle CRO employee turnover? Cathy Gooch, senior VP of people operations and culture at Biorasi, discusses the importance of culture, communication, and connection.

Chief medical officers looking for outsourcing services are often fed lines from large CROs on how they can provide individuals with multitherapeutic backgrounds. Learn to determine which lines are true.

When launching an RFP, refer to this checklist to ensure comprehensive coverage of all aspects when evaluating potential research partners for a rare disease study.

Demystify the mystical by uncovering the mystery in clinical trial logistics. Get answers on how sponsors select a provider, what activities they outsource most, and where the questions are heading.